Pathogen safety of long-term treatments for bleeding disorders: Still relevant to current practice

Haematologica

Volumn 98, Issue 10, 2013, Pages 1495-1498

  Di Minno, Giovanni ^a   Canaro, Mariana ^b   Ironside, James W ^c   Navarro, David ^d   Perno, Carlo Federico ^e   Tiede, Andreas ^f   Gürtler, Lutz ^g  

^a AUP Federico II   (Italy)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA; GLUCOSYLCERAMIDASE;

AFIBRINOGENEMIA; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD DONOR; DISEASE TRANSMISSION; EDITORIAL; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIFE EXPECTANCY; MICROORGANISM DETECTION; MORTALITY; PROTHROMBIN DEFICIENCY; SAFETY; VARIANT CREUTZFELDT JAKOB DISEASE; VON WILLEBRAND DISEASE;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HEMOPHILIA A; HEMORRHAGIC DISORDERS; HUMANS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884924159     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084145     Document Type: Editorial

References (20)

1. Svicher V, Cento V, Bernassola M, Neumann-Fraune M, Van Hemert F, Chen M, et al. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res. 2012;93(1):86-93.
2. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81(1):82-93.
3. Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol. 2007;165(12):1443-53.
4. Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia. 2010;16(3):437-46.
5. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Lee CA, Makris M, et al. The impact of HIV on mortality rates in the complete UK haemophilia population. AIDS. 2004;18(3):525-33.
6. Fransen van de Putte DE, Fischer K, Pulles AE, Roosendaal G, Biesma DH, Schutgens RE, et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res. 2012;130(2):157-62.
7. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol. 2001;66(4):229-40.
8. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006;367(9506):252-61.
9. Soucie JM, De Staercke C, Monahan PE, Recht M, Chitlur MB, Gruppo R, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53(6):1217-25.
10. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006;4(3):510-6.
11. Trimble SR, Parker CS, Grant AM, Soucie JM, Reyes N. Assessing emerging infectious threats to blood safety for the blood disorders community. Am J Prev Med. 2010;38(4 Suppl):S468-74.
12. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012;119(18):4108-14.
13. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasmafree manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201.
14. Sahlberg AS, Granfors K, Penttinen MA. HLA-B27 and host-pathogen interaction. Adv Exp Med Biol. 2009;649:235-44.
15. Kaur P, Basu S. Transfusion-transmitted infections: existing and emerging pathogens. J Postgrad Med. 2005;51(2):146-51.
16. Zappa A, Amendola A, Romano L, Zanetti A. Emerging and re-emerging viruses in the era of globalisation. Blood Transfus. 2009;7(3):167-71.
17. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. 2011; Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Position_statement/2011/06/WC5001 08071.pdf
18. Powell JS. Recombinant factor VIII in the management of hemophilia A: current use and future promise. Ther Clin Risk Manag. 2009;5(2):391-402.
19. Kessler CM. New perspectives in hemophilia treatment. Hematology Am Soc Hematol Educ Program. 2005:429-35.
20. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther 2012;6:81-106.